Manifold Secures $18M Series B Funding Led by Reach Capital

Why It Matters

The infusion of capital validates vertical AI’s strategic value in drug development, enabling faster, compliant pipelines for biopharma and research institutions. It signals heightened investor confidence in AI‑driven life‑science solutions.

Key Takeaways

• Manifold raised $18M Series B, total $40M funding.
• Reach Capital led round, joined by SilverArc and others.
• Platform targets AI-driven drug discovery and clinical workflows.
• Life‑science firms gain faster target identification, market access.
• Governance compliance remains core to Manifold’s AI solutions.

Pulse Analysis

Vertical AI is reshaping niche markets, and Manifold’s latest Series B underscores that trend. Investors are increasingly allocating capital to specialized platforms that combine deep domain expertise with machine‑learning capabilities. By securing $18 million, Manifold joins a cohort of life‑science AI firms that have attracted sizable funding, reflecting confidence that tailored AI can outperform generic models in drug discovery and development pipelines.

For biopharma companies and academic research centers, Manifold’s platform promises tangible efficiency gains. Its tools streamline target identification, reduce cycle times in clinical trials, and enhance market‑access strategies, all while adhering to strict regulatory governance. These capabilities translate into faster progression of promising therapeutics to patients, potentially lowering R&D costs and improving return on investment for drug developers.

The broader market impact extends beyond immediate customers. As Manifold scales, competitors will need to match its integrated compliance framework and end‑to‑end workflow coverage. The funding also positions the company to expand globally, forge deeper partnerships with major pharmaceutical players, and invest in next‑generation AI models. In an industry where speed and precision are paramount, Manifold’s growth could accelerate the overall pace of innovation in precision medicine.

Deal Summary

Manifold, an AI platform for life sciences, announced an $18 million Series B round on December 18, 2025. The round was led by Reach Capital with participation from SilverArc Capital, Industry Ventures, TQ Ventures and Calibrate Ventures, bringing total capital raised to $40 million.